Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

70.36 -0.78 (-1.10%)
Streaming Delayed Price Updated: 11:05 AM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 776,903
Open 70.74
Bid (Size) 70.30 (2)
Ask (Size) 70.41 (2)
Prev. Close 71.14
Today's Range 69.09 - 71.00
52wk Range 37.55 - 76.19
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool

Performance

YTD
+71.60%
+71.60%
1 Month
+36.40%
+36.40%
3 Month
+37.71%
+37.71%
6 Month
+12.07%
+12.07%
1 Year
+38.55%
+38.55%

More News

Read More
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
Via The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
Via Benzinga
Is CRISPR Therapeutics the Best Gene-Editing Stock?
Via The Motley Fool
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Via The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
Via Talk Markets
Topics ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
Via Benzinga
Topics ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
Via Benzinga
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Via InvestorPlace
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
Via The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.